Navigation Links
HeartWare Schedules First Quarter Conference Call And Webcast
Date:4/15/2013

FRAMINGHAM, Mass. and SYDNEY, April 15, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2013, at 5:00 p.m. U.S. Eastern Daylight Time on Monday, April 29, 2013. The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the first quarter and business outlook.  The call may be accessed by dialing 1-877-941-4774 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9760.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare First Quarter 2013 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries.  The device is also currently the subject of a U.S. clinical trial for destination therapy.  For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Completes Acquisition Of World Heart Corporation
9. HeartWare Reports Second Quarter 2012 Results
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... PRUSSIA, Pa. , March 1, 2017  Global ... it has completed the largest ever Chronic Inflammatory Demyelinating ... A nd T reatment with H ... designed to demonstrate the efficacy, safety and tolerability of ... Hizentra ® (Immune Globulin Subcutaneous [Human]), compared with ...
(Date:3/1/2017)... Pharmaceutical Care Management Association (PCMA) issued the following statement ... nomination of Seema Verma as the new ... "The popular Medicare Part D program continues to ... offering an abundance of competing plan choices in each ... and home delivery, the program is a win-win for ...
(Date:3/1/2017)... global  Intraoperative Neuromonitoring (IONM) market  is expected to reach USD 3.6 billion by ... neuromonitoring market is anticipated to witness significant growth in the forecast period, which ... of surgeries. Continue Reading ... ... ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... Physicians’ ... on April 8, 2017, in Sunny Isles Beach, Florida. The conference will be ... Physicians Organization, Boston, and Dr. Heather Wakelee, associate professor of medicine (oncology), Stanford ...
(Date:3/1/2017)... Texas (PRWEB) , ... March 01, 2017 , ... Hennessey Performance (HPE) today announced its ... bumped the Ford EcoBoost 3.5L twin turbo V6 engine from 450 bhp and 510 lb-ft ... twist yield a 0-60 mph time of just 4.2 seconds while running down the ¼ ...
(Date:3/1/2017)... ... 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is proud to announce ... Nashville, Tenn. The company also is offering a special discount for those who attend ... year, brings together the brightest minds in the healthcare industry to share information on ...
(Date:3/1/2017)... ... , ... Look for a new collection of edible berry plants from the ... and Plants is launching their new Bushel and Berry Collection , formerly BrazelBerries, ... growing fresh fruit simple with a variety of easy-to-grow, low-maintenance container berry plants. These ...
(Date:3/1/2017)... ... ... On January 27, 2017, Laffey, Bucci & Kent together with a local ... Circuit Court of Kanawha County, West Virginia. The lawsuit was filed on behalf of ... and T.B. v. Seventh-Day Adventist Church et al. Case #: 17-C-146. , ...
Breaking Medicine News(10 mins):